FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114741307> ?p ?o ?g. }

• W2114741307 endingPage "8" @default.
• W2114741307 startingPage "7" @default.
• W2114741307 abstract "This retrospective analysis concerned 374 patients (pts) who underwent an allo-HSCT for CLL reported to the EBMT registry. There were 282 M and 92 F, median age 53 years (24–69). The interval diag-transp. was 53 months (3–308). Forty five pts (12%) have received a previous HSCT. At transplant, 302 among 323 evaluated pts had a good performance status (PS) (93%), 51 pts were in CR (14%), 163 in PR (45.5%), 39 in SD (11.5%) and 105 in PD (29%) among 353 evaluated pts. As conditioning, 292 pts received a standard (std) one and 82 RIC; 314 pts received PBSC, 55 BM and 5 cord blood cells from 202 HLA siblings (Sib), 2 mismatched related donors and 170 unrelated donors (UD). There were 136 (36%) sex-mismatched, 150 pairs (40%) had an ABO incomp. (61 min., 99 maj.). There were 359 pts engrafted, 201 AGVHD (gr I: 76, gr II : 79 , gr III: 30 and gr IV:16) and 15 cGVHD (75 lim., 78 ext.). At day 100, the cumulative incidence (CI) of AGVHD for the total population was 17% (13–22) for gr I, 31% (26–36) for gr ≥ II. [Sib: 19% (13–25) gr I and 27% (21–34) gr ≥ II; UD: 16% (9–22) gr I and 38% (29–47) gr ≥ II ].Table 1Cumulative incidence of AGVHD, NRM and Relapse according to HLA typing and kind of conditioningRICStdHLA siblings AGVHD (D100) Gr I15% [9-20,5]34% [19-49] Gr II15% [9-21,4]19,5% [7-49] Gr III-IV11% [6-16]12% [2-22] NRM at 1 year18,4% [12-25]23% [11-35.6] Relapse at 1 year13% [8 -19]6% [0-14]Unrelated Donors AGVHD (D100) Gr I13% [6-20]22% [4-39] Gr II22% [13-30]26% [7,5-45] Gr III-IV14% [7-21]22% [4-39] NRM at 1 year24% [16-32]36% [17-55] Relapse at 1 year16% [9-23]4% [0-12] Open table in a new tab ... The CI of lim. and ext. cGVHD at 1 yr, were 15 % (6–24) and 29.5% (18–41) for Std; 18.6 (13–24) and 18% (13–23) for RIC respectively. With a median follow up of 38 months, the 3 and 5-yr OS and DFS were 56% (51–62) and 47.4 % (42–53); 49 % (43–56) and 42% (36–48.5) respectively. We observed a significant difference concerning 5-yr OS according to the pretransplant disease status [CR: 73% (60–89), PR: 57% (48–68) and PD: 35% (26–46)] (p<0.00001).There was no significant difference between std and RIC in term of OS with 52.4 % (42–66) and 47% (40–55.5) respectively (p = 0.44) [Std and RIC Sib: 51% (37–70) and 56% (47–67); Std and RIC UD: 60% (44–83) and 40% (29–55) respectively]. The multivariate analysis showed a significant impact of 3 factors on OS: age: HR = 1.061 (1.02–1.10) p<0.0001, gender: HR = 2.29 (1.02–5.11) p = 0.04 and PS: HR = 3.15 (1.40–7.10) p = 0.005.The CI of non-relapse and relapse mortality (NRM and RM) at 3 months and 1 yr were: 10 % (7–13), 5% (3–7) and 24% (19–28), 15% (12–19) respectively [Std:23 % (11–35.6), 6% (0–14) 1 year; RIC: 22.5% (17.5–27), 18% (13–22) at 1 year]. We showed a high percentage of long-term OS after HSCT for CLL either after Std or RIC without any difference between the 2 groups except for the AGVHD and an important impact of disease status pretransplant; age, PS and sex-matching on the global OS." @default.
• W2114741307 created "2016-06-24" @default.
• W2114741307 creator A5003455280 @default.
• W2114741307 creator A5005481013 @default.
• W2114741307 creator A5027302651 @default.
• W2114741307 creator A5031769736 @default.
• W2114741307 creator A5031825598 @default.
• W2114741307 creator A5034008882 @default.
• W2114741307 creator A5042734609 @default.
• W2114741307 creator A5058677948 @default.
• W2114741307 creator A5062694494 @default.
• W2114741307 creator A5062839406 @default.
• W2114741307 creator A5072027146 @default.
• W2114741307 creator A5076329357 @default.
• W2114741307 creator A5076734375 @default.
• W2114741307 creator A5078402436 @default.
• W2114741307 creator A5085132315 @default.
• W2114741307 creator A5085146093 @default.
• W2114741307 creator A5087870886 @default.
• W2114741307 date "2009-02-01" @default.
• W2114741307 modified "2023-10-18" @default.
• W2114741307 title "Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) From Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). A Long-Term Follow-Up (10 Years) Study From the EBMT Registry" @default.
• W2114741307 doi "https://doi.org/10.1016/j.bbmt.2008.12.021" @default.
• W2114741307 hasPublicationYear "2009" @default.
• W2114741307 type Work @default.
• W2114741307 sameAs 2114741307 @default.
• W2114741307 citedByCount "1" @default.
• W2114741307 crossrefType "journal-article" @default.
• W2114741307 hasAuthorship W2114741307A5003455280 @default.
• W2114741307 hasAuthorship W2114741307A5005481013 @default.
• W2114741307 hasAuthorship W2114741307A5027302651 @default.
• W2114741307 hasAuthorship W2114741307A5031769736 @default.
• W2114741307 hasAuthorship W2114741307A5031825598 @default.
• W2114741307 hasAuthorship W2114741307A5034008882 @default.
• W2114741307 hasAuthorship W2114741307A5042734609 @default.
• W2114741307 hasAuthorship W2114741307A5058677948 @default.
• W2114741307 hasAuthorship W2114741307A5062694494 @default.
• W2114741307 hasAuthorship W2114741307A5062839406 @default.
• W2114741307 hasAuthorship W2114741307A5072027146 @default.
• W2114741307 hasAuthorship W2114741307A5076329357 @default.
• W2114741307 hasAuthorship W2114741307A5076734375 @default.
• W2114741307 hasAuthorship W2114741307A5078402436 @default.
• W2114741307 hasAuthorship W2114741307A5085132315 @default.
• W2114741307 hasAuthorship W2114741307A5085146093 @default.
• W2114741307 hasAuthorship W2114741307A5087870886 @default.
• W2114741307 hasConcept C120665830 @default.
• W2114741307 hasConcept C121332964 @default.
• W2114741307 hasConcept C126322002 @default.
• W2114741307 hasConcept C141071460 @default.
• W2114741307 hasConcept C2777408962 @default.
• W2114741307 hasConcept C2777938653 @default.
• W2114741307 hasConcept C2778461978 @default.
• W2114741307 hasConcept C2908647359 @default.
• W2114741307 hasConcept C2911091166 @default.
• W2114741307 hasConcept C61511704 @default.
• W2114741307 hasConcept C71924100 @default.
• W2114741307 hasConcept C88879693 @default.
• W2114741307 hasConcept C90924648 @default.
• W2114741307 hasConcept C99454951 @default.
• W2114741307 hasConceptScore W2114741307C120665830 @default.
• W2114741307 hasConceptScore W2114741307C121332964 @default.
• W2114741307 hasConceptScore W2114741307C126322002 @default.
• W2114741307 hasConceptScore W2114741307C141071460 @default.
• W2114741307 hasConceptScore W2114741307C2777408962 @default.
• W2114741307 hasConceptScore W2114741307C2777938653 @default.
• W2114741307 hasConceptScore W2114741307C2778461978 @default.
• W2114741307 hasConceptScore W2114741307C2908647359 @default.
• W2114741307 hasConceptScore W2114741307C2911091166 @default.
• W2114741307 hasConceptScore W2114741307C61511704 @default.
• W2114741307 hasConceptScore W2114741307C71924100 @default.
• W2114741307 hasConceptScore W2114741307C88879693 @default.
• W2114741307 hasConceptScore W2114741307C90924648 @default.
• W2114741307 hasConceptScore W2114741307C99454951 @default.
• W2114741307 hasIssue "2" @default.
• W2114741307 hasLocation W21147413071 @default.
• W2114741307 hasOpenAccess W2114741307 @default.
• W2114741307 hasPrimaryLocation W21147413071 @default.
• W2114741307 hasRelatedWork W2004368639 @default.
• W2114741307 hasRelatedWork W2009733242 @default.
• W2114741307 hasRelatedWork W2120351292 @default.
• W2114741307 hasRelatedWork W2161996216 @default.
• W2114741307 hasRelatedWork W2357142827 @default.
• W2114741307 hasRelatedWork W2360260519 @default.
• W2114741307 hasRelatedWork W2415666441 @default.
• W2114741307 hasRelatedWork W2534679415 @default.
• W2114741307 hasRelatedWork W2614629048 @default.
• W2114741307 hasRelatedWork W2794187412 @default.
• W2114741307 hasVolume "15" @default.
• W2114741307 isParatext "false" @default.
• W2114741307 isRetracted "false" @default.
• W2114741307 magId "2114741307" @default.
• W2114741307 workType "article" @default.